Description
Histone Therapeutics' “ON” platform enables precise gene activation through transient mRNA delivery via non-viral vectors. By restoring or amplifying gene expression, they can address diseases without altering DNA or introducing long-lasting genetic material.
Team Members
Shiri Levy
CSO
Greg Block
CEO